Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Brodalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis. (Funded by Amgen; AMAGINE-2 and AMAGINE-3 ClinicalTrials.gov numbers, NCT01708603 and NCT01708629.).

Leer artículo completoexternamente

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Cite This Study

Lebwohl et al. (Wed,) studied this question.

synapsesocial.com/papers/69d76b0fb1cb92dd1bb8b0f4 https://doi.org/https://doi.org/10.1056/nejmoa1503824

Discussion

Journals

New England Journal of Medicine

Institutions

Harvard University

University of California, San Francisco

Massachusetts General Hospital

References and Citations

Add This Paper to Your Research Feed

Any time a new paper drops it will be there.